|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
2 months to Dec 31, 2023
|
FY2023
12 months to Oct 31, 2023
|
FY2022
12 months to Oct 31, 2022
|
|
|---|---|---|---|---|---|
| Cost of finished cannabis inventory sold | |||||
| Cost of service revenues | |||||
| Gross profit, excluding fair value items | |||||
| Realized fair value loss amounts in inventory sold | |||||
| Unrealized fair value gain on growth of biological assets | |||||
| Amortization of property and equipment | |||||
| General and administrative | |||||
| Share-based compensation | |||||
| Total expenses | |||||
| Income from operations | |||||
| Interest expense | |||||
| Accretion expense | |||||
| Other income (expense) | |||||
| Gain on extinguishment of note receivable | |||||
| Unrealized gain (loss) on derivative liability | |||||
| Unrealized gain on warrants asset | |||||
| Loss on equity investment in associate | |||||
| Gain (loss) on disposal of property and equipment | |||||
| Total other expense, net | |||||
| Income (loss) from operations before taxes | |||||
| Income tax (Note 20) | |||||
| Revenue | |||||
| Product | |||||
| Service | |||||
| Products | |||||
| Services | |||||
| Total revenue | |||||
| Cost of goods sold | |||||
| Cost of finished cannabis inventory sold | |||||
| Costs of service revenue | |||||
| Total cost of goods sold | |||||
| Gross profit | |||||
| Operating expenses | |||||
| Amortization (Notes 10, 11) | |||||
| General and administrative | |||||
| Share-based compensation expense | |||||
| Total operating expenses | |||||
| Income (loss) from operations | |||||
| Other income (expense) | |||||
| Interest expense (Note 13,15) | |||||
| Accretion expense (Notes 13,14,15) | |||||
| Other income (Note 11) | |||||
| Interest income (Note 9) | |||||
| Unrealized gain (loss) on derivative liability (Note 16) | |||||
| Realized gain (loss) on derivative liability (Note 16) | |||||
| Unrealized gain on warrant asset (Note 7) | |||||
| Realized loss on warrant liability (Note 17) | |||||
| Loss on equity investment in associate (Note 8) | |||||
| Total other income (expense), net | |||||
| Income (loss) before income tax expense | |||||
| Income tax expense (Note 22) | |||||
| Net income (loss) | |||||
| Currency translation adjustment | |||||
| Total comprehensive income (loss) | |||||
| Income (loss) per share basic | |||||
| Income (loss) per share diluted | |||||
| Basic weighted average number of subordinate voting common shares outstanding | |||||
| Diluted weighted average number of subordinate voting common shares outstanding | |||||
| Net income (loss) for the period attributable to: | |||||
| Shareholders | |||||
| Non-controlling interest | |||||
| Currency translation gain (loss) | |||||
| Gain (loss) per share attributable to shareholders – basic and diluted | |||||
| Gain (loss) per share attributable to shareholders – basic | |||||
| Weighted average shares outstanding – basic | |||||
| Gain (loss) per share attributable to shareholders – diluted | |||||
| Weighted average shares outstanding – diluted | |||||
| Non-controlling interest | |||||
| Shareholders | |||||
| Comprehensive income (loss) for the period attributable to: | |||||
| Shareholders | |||||
| Non-controlling interest | |||||
Loading...